Genmab A-S Aktie

253,20 EUR +0,80 EUR +0,32 %

15:01:37

STU

253,00 EUR +0,60 EUR +0,24 %

15:05:48

GVIE

Genmab A-S jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.15,98 Mrd. EUR

KGV12,21Div. Rendite0,00%

WKN565131

ISINDK0010272202

SymbolGNMSF

Genmab A-S Aktien News

Sortieren:Datum Meistgelesen

03.06.24GlobeNewswireInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

02.06.24GlobeNewswirePreliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

01.06.24GlobeNewswireInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-smal

27.05.24GlobeNewswireTransactions in Connection with Share Buy-back Program

23.05.24GlobeNewswireGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

21.05.24GlobeNewswireGenmab Completes Acquisition of ProfoundBio

21.05.24GlobeNewswireTransactions in Connection with Share Buy-back Program

14.05.24GlobeNewswireGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress

13.05.24GlobeNewswireTransactions in Connection with Share Buy-back Program

07.05.24GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

06.05.24GlobeNewswireTransactions in Connection with Share Buy-back Program

02.05.24GlobeNewswireGenmab Announces Financial Results for the First Quarter of 2024

30.04.24GlobeNewswireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

29.04.24GlobeNewswireTransactions in Connection with Share Buy-back Program Genmab

22.04.24GlobeNewswireTransactions in Connection with Share Buy-back Program Genmab

16.04.24GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024

15.04.24GlobeNewswireTransactions in Connection with Share Buy-back Program Genmab

08.04.24GlobeNewswireTransactions in Connection with Share Buy-back Program

03.04.24GlobeNewswireGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio

02.04.24GlobeNewswireTransactions in Connection with Share Buy-back Program

25.03.24GlobeNewswireTransactions in Connection with Share Buy-back Program

18.03.24GlobeNewswireCompletion of share buy-back program

15.03.24GlobeNewswireGenmab Announces Initiation of Share Buy-Back Program

13.03.24GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

13.03.24GlobeNewswireConstitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

13.03.24GlobeNewswirePassing of Genmab A/S’ Annual General Meeting

11.03.24GlobeNewswireTransactions in connection with share buy-back program

04.03.24GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

04.03.24GlobeNewswireTransactions in connection with share buy-back program

02.03.24GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

29.02.24GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

27.02.24GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

27.02.24GlobeNewswireCapital Increase in Genmab as a Result of Employee Warrant Exercise

27.02.24GlobeNewswireU.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma

26.02.24GlobeNewswireTransactions in connection with share buy-back program

23.02.24GlobeNewswireTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

23.02.24GlobeNewswireGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

19.02.24GlobeNewswireTransactions in connection with share buy-back program

15.02.24GlobeNewswireNotice to Convene the Annual General Meeting of Genmab A/S

14.02.24GlobeNewswireGenmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab A-S News

Genmab A-S News: auf dieser Seite finden Sie alle Genmab A-S News und Nachrichten zur Genmab A-S Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Genmab A-S News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Genmab A-S News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.